Literature DB >> 8251653

Protein tyrosine kinase activity as a prognostic parameter in breast cancer, a pilot study.

M Bolla1, B R Rostaing-Puissant, M Chedin, C Souvignet, J Marron-Charriere, M Colonna, E Berland, E M Chambaz.   

Abstract

Protein tyrosine kinase (PTK) activity was assayed in cytosolic extracts from normal breast tissue, benign tumors, and 84 T1-T2, N0-N1 M0, breast carcinomas. Normal breast tissue extracts yielded an average value of 1.9 +/- 1.1 pmol 32P incorporated/min/mg protein, whereas a mean of 12.5 +/- 6.1 was obtained for cancer samples. With a median follow-up of 34 months, in the series of 40 patients classified N-, PTK positive patients presented a significantly smaller 3-year disease free survival than the PTK negative ones. Multivariate analysis shows that PTK activity emerges as a potential prognostic factor in breast cancer (p = 0.02). These preliminary results will be updated on a bigger cohort of patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8251653     DOI: 10.1007/bf00665806

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  12 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Breast cancer prognostic factors: evaluation guidelines.

Authors:  W L McGuire
Journal:  J Natl Cancer Inst       Date:  1991-02-06       Impact factor: 13.506

Review 3.  A thousand and one protein kinases.

Authors:  T Hunter
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

Review 4.  Growth factor receptor tyrosine kinases.

Authors:  Y Yarden; A Ullrich
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

Review 5.  Protein-tyrosine kinases.

Authors:  T Hunter; J A Cooper
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

6.  Protein tyrosine kinases in human breast cancer: kinetic properties and evidence for the presence of two forms of native enzyme.

Authors:  Y Durocher; S Chevalier
Journal:  Breast Cancer Res Treat       Date:  1990-12       Impact factor: 4.872

7.  Estimation of epidermal growth factor receptor in 177 breast cancers: correlation with prognostic factors.

Authors:  M Bolla; M Chedin; C Souvignet; J Marron; C Arnould; E Chambaz
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

8.  [Estradiol and progesterone receptors in loco-regional breast cancer. Clinical and prognostic correlations].

Authors:  M Bolla; M Chedin; E Chambaz; P Gabelle
Journal:  Sem Hop       Date:  1984-01-19

9.  Integrating prognostic factors.

Authors:  G M Clark
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

10.  Epidermal growth factor receptor in human breast cancers: correlation with estrogen and progesterone receptors.

Authors:  J C Delarue; S Friedman; H Mouriesse; F May-Levin; H Sancho-Garnier; G Contesso
Journal:  Breast Cancer Res Treat       Date:  1988-05       Impact factor: 4.872

View more
  3 in total

1.  Protein tyrosine kinase activity in 350 T1/T2, N0/N1 breast cancer. Preliminary results.

Authors:  M Bolla; B Rostaing-Puissant; S P Bottari; M Chedin; J Marron-Charriere; M Colonna; E Berland; E Chambaz
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.

Authors:  Kristopher A Lofgren; Julie H Ostrander; Daniel Housa; Gregory K Hubbard; Alessia Locatelli; Robin L Bliss; Kathryn L Schwertfeger; Carol A Lange
Journal:  Breast Cancer Res       Date:  2011-09-17       Impact factor: 6.466

3.  Prognostic value of cytosolic tyrosine kinase activity in 249 node-positive breast cancer patients.

Authors:  S Romain; O Chinot; J G Klijn; W L van Putten; O Guirou; M Look; P M Martin; J A Foekens
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.